OncoC4, Inc. Email Format

Biotechnology ResearchMaryland, United States51-200 Employees

OncoC4, Inc. is a privately held, late clinical-stage biopharmaceutical company based in Rockville, Maryland, focused on discovering and developing novel biologics for cancer. Its lead clinical candidate, BNT316/ONC-392, is described as a next-generation anti-CTLA-4 antibody intended to allow CTLA-4 to recycle and preserve its protective function against autoimmune diseases while boosting anti-tumor activity. The company also maintains a pipeline of preclinical candidates targeting the CD24-Siglecs cancer immune evasion pathway. Within the pharmaceutical manufacturing sector, OncoC4 pursues therapies for cancer, including solid tumor indications related to its ONC-392 program. It has engaged in strategic collaboration with BioNTech to co-develop and commercialize ONC-392 in multiple solid tumor indications. The organization operates with a mid-sized team and participates in industry events and partnerships to advance its research agenda.

Get verified OncoC4, Inc. emails free

Company overview Employee directory